These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1177 related items for PubMed ID: 12063860

  • 1. [Novel pharmacologic therapies in acromegaly].
    Góth M, Hubina E, Kovács L, Szabolcs I.
    Orv Hetil; 2002 May 12; 143(19 Suppl):1057-62. PubMed ID: 12063860
    [Abstract] [Full Text] [Related]

  • 2. [Current alternative in the pharmacotherapy of acromegaly: the long-acting somatostatin analogue octreotide].
    Laczi F, Magony S, Julesz J.
    Orv Hetil; 2002 May 12; 143(19 Suppl):1062-6. PubMed ID: 12063861
    [Abstract] [Full Text] [Related]

  • 3. Pharmacological management of acromegaly: a current perspective.
    Manjila S, Wu OC, Khan FR, Khan MM, Arafah BM, Selman WR.
    Neurosurg Focus; 2010 Oct 12; 29(4):E14. PubMed ID: 20887124
    [Abstract] [Full Text] [Related]

  • 4. Current pharmacotherapy for acromegaly: a review.
    Biermasz NR, Romijn JA, Pereira AM, Roelfsema F.
    Expert Opin Pharmacother; 2005 Nov 12; 6(14):2393-405. PubMed ID: 16259571
    [Abstract] [Full Text] [Related]

  • 5. In vivo and in vitro effects of octreotide, quinagolide and cabergoline in four hyperprolactinaemic acromegalics: correlation with somatostatin and dopamine D2 receptor scintigraphy.
    Ferone D, Pivonello R, Lastoria S, Faggiano A, Del Basso de Caro ML, Cappabianca P, Lombardi G, Colao A.
    Clin Endocrinol (Oxf); 2001 Apr 12; 54(4):469-77. PubMed ID: 11318782
    [Abstract] [Full Text] [Related]

  • 6. [Treatment of pituitary adenomas].
    Mezosi E, Nemes O.
    Orv Hetil; 2009 Sep 27; 150(39):1803-10. PubMed ID: 19758960
    [Abstract] [Full Text] [Related]

  • 7. [Optimization of the medical treatment for acromegaly].
    Díez JJ, Iglesias P.
    Med Clin (Barc); 2013 Apr 20; 140(8):360-5. PubMed ID: 23103101
    [Abstract] [Full Text] [Related]

  • 8. Long-term safety and treatment outcomes of pegvisomant in Japanese patients with acromegaly: results from the post-marketing surveillance.
    Yamaguchi H, Shimatsu A, Okayama A, Sato T.
    Endocr J; 2020 Feb 28; 67(2):201-210. PubMed ID: 31723069
    [Abstract] [Full Text] [Related]

  • 9. Comparison of octreotide acetate LAR and lanreotide SR in patients with acromegaly.
    Chanson P, Boerlin V, Ajzenberg C, Bachelot Y, Benito P, Bringer J, Caron P, Charbonnel B, Cortet C, Delemer B, Escobar-Jiménez F, Foubert L, Gaztambide S, Jockenhoevel F, Kuhn JM, Leclere J, Lorcy Y, Perlemuter L, Prestele H, Roger P, Rohmer V, Santen R, Sassolas G, Scherbaum WA, Schopohl J, Torres E, Varela C, Villamil F, Webb SM.
    Clin Endocrinol (Oxf); 2000 Nov 28; 53(5):577-86. PubMed ID: 11106918
    [Abstract] [Full Text] [Related]

  • 10. Newer options in the management of acromegaly.
    Burt MG, Ho KK.
    Intern Med J; 2006 Jul 28; 36(7):437-44. PubMed ID: 16780450
    [Abstract] [Full Text] [Related]

  • 11. Medical treatment of acromegaly: comorbidities and their reversibility by somatostatin analogs.
    Tolis G, Angelopoulos NG, Katounda E, Rombopoulos G, Kaltzidou V, Kaltsas D, Protonotariou A, Lytras A.
    Neuroendocrinology; 2006 Jul 28; 83(3-4):249-57. PubMed ID: 17047390
    [Abstract] [Full Text] [Related]

  • 12. [Drug therapy for acromegaly].
    Góth M.
    Orv Hetil; 2013 Sep 29; 154(39):1527-34. PubMed ID: 24058097
    [Abstract] [Full Text] [Related]

  • 13. [Experience in treating acromegalic patients with long-acting octreotide].
    Szücs N, Mészáros J, Czirják S, Mondok A, Varga I, Gláz E.
    Orv Hetil; 2002 May 12; 143(19 Suppl):1066-70. PubMed ID: 12063862
    [Abstract] [Full Text] [Related]

  • 14. Somatostatin analogues in acromegaly and gastroenteropancreatic neuroendocrine tumours: past, present and future.
    Öberg K, Lamberts SW.
    Endocr Relat Cancer; 2016 Dec 12; 23(12):R551-R566. PubMed ID: 27697899
    [Abstract] [Full Text] [Related]

  • 15. Efficacy and safety of high-dose long-acting repeatable octreotide as monotherapy or in combination with pegvisomant or cabergoline in patients with acromegaly not adequately controlled by conventional regimens: results of an open-label, multicentre study.
    Colao A, Zgliczyński W, Komorowski J, Kos-Kudła B, Tabarin A, Kerlan V, Minuto FM, Scaroni C, Bolanowski M.
    Endokrynol Pol; 2019 Dec 12; 70(4):305-312. PubMed ID: 31274183
    [Abstract] [Full Text] [Related]

  • 16. Control of tumor size and disease activity during cotreatment with octreotide and the growth hormone receptor antagonist pegvisomant in an acromegalic patient.
    van der Lely AJ, Muller A, Janssen JA, Davis RJ, Zib KA, Scarlett JA, Lamberts SW.
    J Clin Endocrinol Metab; 2001 Feb 12; 86(2):478-81. PubMed ID: 11157994
    [Abstract] [Full Text] [Related]

  • 17. Cabergoline addition to depot somatostatin analogues in resistant acromegalic patients: efficacy and lack of predictive value of prolactin status.
    Cozzi R, Attanasio R, Lodrini S, Lasio G.
    Clin Endocrinol (Oxf); 2004 Aug 12; 61(2):209-15. PubMed ID: 15272916
    [Abstract] [Full Text] [Related]

  • 18. Additional metabolic effects of adding GH receptor antagonist to long-acting somatostatin analog in patients with active acromegaly.
    Jawiarczyk A, Kałuzny M, Bolanowski M, Bednarek-Tupikowska G.
    Neuro Endocrinol Lett; 2008 Aug 12; 29(4):571-6. PubMed ID: 18766168
    [Abstract] [Full Text] [Related]

  • 19. Pharmacological approach to the treatment of acromegaly.
    Ezzat S.
    Neurosurg Focus; 2004 Apr 15; 16(4):E3. PubMed ID: 15191332
    [Abstract] [Full Text] [Related]

  • 20. Pasireotide versus continued treatment with octreotide or lanreotide in patients with inadequately controlled acromegaly (PAOLA): a randomised, phase 3 trial.
    Gadelha MR, Bronstein MD, Brue T, Coculescu M, Fleseriu M, Guitelman M, Pronin V, Raverot G, Shimon I, Lievre KK, Fleck J, Aout M, Pedroncelli AM, Colao A, Pasireotide C2402 Study Group.
    Lancet Diabetes Endocrinol; 2014 Nov 15; 2(11):875-84. PubMed ID: 25260838
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 59.